Biohealth Innovation
When it comes to capturing venture capital funding Maryland tops the region in both deals and dollars.
In a ranking of all 50 states and D.C., Maryland ranked No. 11 in venture capital funding in the third quarter of 2015. It ranked No. 7 in its share of nationwide deals during the same time.
The U.S. Department of Commerce’s Commercial Service is coordinating participation in the Hannover Messe, the world’s largest Industrial Trade Fair, to be held in April 25-29, 2016 in Hannover, Germany. This year, the United States is the official partner country for the first time and therefore will offer substantial visibility to U.S. based exhibitors who participate in any of the five trade shows, including one for Research and Technology, as well as an Investment Pavilion.
The Research & Technology trade show would be a great platform for U.S. Exhibitors, including Large and Start-up Companies, Academia, Technical Institutions, and Labs, to present their research activities in these fields .
AstraZeneca and Peregrine are expanding their ongoing onco-immunotherapy pact to allow for a Phase II trial of an experimental lung cancer combination treatment.
The companies said they will test a combination of Peregrine’s phosphatidylserine-targeted immune-activator bavituximab and AZ’ anti-PD-L1 immune checkpoint inhibitor durvalumab (MEDI4736) in a global Phase II study in patients with previously treated squamous or non-squamous non-small cell lung cancer.
M Square, the University of Maryland Research Park, won this year’s Association of University Research Parks’ Outstanding Research Park award.
The award ceremony took place earlier this month during the AURP Annual Awards of Excellence at the Buffalo Niagara Medical Campus in New York.
Silver Spring-based United Therapeutics Corp. on Thursday announced its board had authorized the repurchase of up to an additional $500 million worth of its common stock, for as long as a year, starting Jan. 1. Purchases may be made in the open market or in privately negotiated transactions from time to time as determined by the ...
An entrepreneur as well as a scientist, Kunal Parikh has spent years developing drug-delivery platforms to improve patient treatment. He plans to spend the next year pursuing patents for these technologies; submitting his research for publication in scholarly journals; visiting hospitals and manufacturing plants to conduct implementation research; and continuing to lead and mentor the team of scientists, engineers, and clinicians who work alongside him.
One year doesn't seem like enough time.
The kind of opportunity that technology and energy markets once offered is beckoning investors to property near biotech clusters. Emerging from the recession, technology and energy markets commanded the attention of commercial real-estate investors that wanted to tap into improving occupancy and rental rates largely absent elsewhere.
A similar dynamic is germinating in biotech clusters, which are typically marked by a high concentration of life-science companies near academic research institutions.
Trade-Ideas LLC identified Sucampo Pharmaceuticals ( SCMP) as a "dead cat bounce" (down big yesterday but up big today) candidate. In addition to specific proprietary factors, Trade-Ideas identified Sucampo Pharmaceuticals as such a stock due to the following factors:
Join us Nov. 19 for the 16th annual Bioscience Day at the University of Maryland, where we'll explore "Systems Biology: Advancing Life Sciences and Medicine."
Registration is free and lunch is provided.
Johns Hopkins researchers on Thursday unveiled a new medical research app that could help them better detect and manage epileptic seizures. The free app, called EpiWatch, is designed for the Apple Watch and iPhones. The app will collect data from patients before, during and after a seizure. Researchers are hopeful that after collecting data for one or two years, they will be able to develop an app that can detect most seizure types and generate an alert to call for help, if needed.
Malvern, Pennsylvania-based Galera Therapeutics, a biotech company focused on treating cancer patients, has closed $37 million in Series B funding. Novo Ventures led the round with participation from previous backers New Enterprise Associates, Novartis Venture Fund, Correlation Ventures and Galera Angels. In conjunction with the funding, Dr. Thomas Dyrberg, a managing partner of Novo Ventures, has been added to Galera’s board of directors.
People can lose their hearing for a variety of reasons, from age to loud noises, but there’s one thing they all have in common. There are no drugs to help them. Several companies have formed in recent years to address this gap, and now there’s another coming to the party a bit late, but with deep pockets—a new startup called Decibel Therapeutics, which is embarking on a broad effort to figure out what makes us go deaf in the first place.
Brian Stansky is the new director of Johns Hopkins’ incubator program for startups, according to a letter sent to colleagues from Christy Wyskiel, senior advisor to the president of Johns Hopkins on entrepreneurship and tech transfer. Nina Urban was appointed as associate director of the program.
Stansky served as interim director of the program for the last two months. He previously worked for 13 years as managing director at Integral Capital Partners, and oversaw health, sciences and media/telecom portfolios at T. Rowe Price.
Join REDI on October 22nd from 8:00-10:00am for the second edition of the Commercial Broker Breakfast (CBB). The CBB event combines networking and a mini trade show that includes local architects, bankers, contractors, interior designers, and other related vendors.
This year's event is highlighted by a discussion with Benjamin Wu, Deputy Secretary for the Maryland Department of Commerce.
AstraZeneca's ($AZN) MedImmune is joining the likes of Vanderbilt University and GlaxoSmithKline ($GSK) as a member of the Human Vaccines Project, the company announced Tuesday.
The public-private partnership, incubated at the International AIDS Vaccine Initiative (IAVI), aims to accelerate the development of vaccines and immunotherapies against major infectious diseases and cancers "by decoding the human immune system."
Resveratrol for the win: Red wine drinkers had better levels of HDL cholesterol, better sleep and lower cardiometabolic risk factors
Why Two Minutes of Lost Footage From 'The Civil War' Documentary… Promoted Why You Should Be Getting Your Wine Online Recommended by Alcohol is the Goldilocks of the nutrition world. Too much can be destructive to your health, raising your blood pressure and your risk of developing several kinds of cancer. Too little may hold you back from some of the benefits that moderate drinkers enjoy, like lower incidence of cardiovascular disease, mortality and type-2 diabetes.
Large pharmaceutical companies are often on the lookout for small strategic acquisitions of companies that have a promising pipeline candidate in their portfolio. Sometimes, acquiring a company with a promising early-stage candidate makes sense instead of developing a product from scratch, which involves a lot of time.
Swiss oncology major Roche RHHBY is all set to acquire a privately held biotechnology company, Adheron Therapeutics. Based in Berkeley, CA, Adheron has developed a revolutionary technology that disrupts cell adhesion to treat a variety of inflammatory and autoimmune diseases, such as rheumatoid arthritis (RA) and fibrotic diseases through a cell surface protein called Cadherin-11.
23andMe has raised a substantial $115 million in a series E round led by Fidelity Management and Research Company, with participation from new investors Casdin Capital, WuXi Healthcare Ventures, and Xfund, as well as existing investors such as Google Ventures.
The personal genomics and biotechnology company was founded in 2006 by Linda Avey and Anne Wojcicki, wife of Google cofounder Sergey Brin. The Mountain View, Calif.-based company had already raised $126 million prior to today’s announcement, and boasts a slew of big-name investors, including Google, Google Ventures, Sergey Brin, and Yuri Milner.
The Association of Public and Land-grant Universities (APLU) today named six public research institutions as finalists for its third annual Innovation & Economic Prosperity (IEP) University Awards. The winners will be announced on November 17 at the association’s annual meeting in Indianapolis. The finalists — Auburn University, Clemson University, Ohio University, University of Illinois, University of Maryland, and University of Minnesota — are competing for four different awards that recognize different components of economic engagement. The award categories include talent, innovation, place, and connections.
In a move that takes concierge medicine to a whole new level, human genome pioneer J. Craig Venter on Tuesday unveiled a venture that combines whole genome sequencing with advanced clinical technologies to provide comprehensive health exams for self-paying customers.
The venture, called Health Nucleus, was formed as part of Human Longevity Inc., also known as HLI, the company Venter founded 19 months ago (with an initial $70 million in venture funding) to provide whole genome sequencing and other diagnostic services.
MedImmune is the newest member of the Human Vaccines Project, which will help to accelerate the research and development of vaccines and immunotherapies for infectious disease and cancer.
Incubated at the International AIDS Vaccine Initiative (IAVI), the Human Vaccines Project is an ambitious new public-private partnership seeking to transform the future of global disease prevention and treatment by solving the primary scientific obstacles impeding the research and development of new vaccines and immunotherapies. Endorsed by 35 leading vaccine scientists, the Project brings together top academic research centers, and government, non-profit and industry research and development efforts into a global consortium.
A $300 million worldwide licensing agreement announced last week between Immunomic Therapeutics and Astellas Pharma to develop treatment for a wide range of allergic diseases, including peanut allergies, is the largest deal ever to come out of Johns Hopkins Technology Ventures, the patent, licensing, and technology commercialization arm of the university.
The agreement, first announced Thursday night, centers on the LAMP-vax technology, which was originally developed by Thomas August, Drew Pardoll, and others at the Johns Hopkins University School of Medicine and licensed in 2006 to Immunomic Therapeutics, a biotech company based in Hershey, Pennsylvania.
Can aging be slowed by using gene therapy to make permanent changes to a person’s DNA?
One Seattle-area woman says she has tried exactly that. Her claim has entangled some high-profile American academics in a strange tale of do-it-yourself medicine that involves plane flights to Latin America, an L.A. film crew, and what’s purported to be the first attempt to use gene therapy to forestall normal aging.
DNA doesn't just coil in the iconic double helix immortalized in every high school biology textbook. It also loops into a menagerie of fantastical shapes, new research finds.
By revealing the hidden shape of DNA, the new insights could provide a more detailed look at the workings of drugs such as chemotherapeutic agents, which interact with DNA.
Attracting mid- to large-sized medical device companies through established innovation hubs is the biggest key to growing Baltimore into a major medical device technology sector, according to a report released today by the Maryland Technology Enterprise Institute (Mtech).
"Baltimore already has many of the pieces in place to support innovation hubs and a thriving medical device community," said Martha Connolly, director of Mtech Baltimore. "This study is important because we believe Baltimore is well-positioned to be a leading center for medical devices. The expertise of the University System of Maryland and Johns Hopkins University in engineering and medicine provide great capabilities for this sector."
WHEN: Tuesday, October 20, 2015 | 6:30pm-8:30pm WHERE: Johns Hopkins East, 1101 East 33rd Street, Baltimore, Maryland 21218 | 3rd Floor Conference Room.
Learn how to secure National Institutes of Health SBIR/STTRs for your high-tech bio-innovation.
Dr. Doswell lead JUICE Money wins for high-tech minority companies and HBCUs such as: 3 NIH SBIR/STTR grant awards in 2015.
Nominations are now being accepted for the 2016 FLC awards. One of the most coveted honors in the technology transfer field, the FLC awards have been presented to over 200 federal laboratories since their inception in 1984. To reflect the diversity in scope and number of technology transfer efforts undertaken by federal laboratories and their partners, seven categories of awards will be presented.
CareFirst BlueCross BlueShield will award $3 million to nonprofits or government organizations to develop new programs using telemedicine to improve health care access in the Maryland, Northern Virginia and D.C.
CareFirst’s request for proposals is looking for innovative programs that can address gaps in access to telemedicine services. The money will be awarded to programs over the next three years.
OpGen, Inc. an early-stage commercial molecular testing and bioinformatics company, today announced that new data from a study with its Acuitas [(R)] Resistome Test were presented on October 10 as an oral abstract at IDWeek 2015 by Michael Lin, M.D., M.P.H., an infectious disease physician and assistant professor of medicine at Rush University Medical Center in Chicago. The conference was held October 7 to 11 in San Diego. Dr. Lin and fellow researchers demonstrated how an Acuitas Resistome-based surveillance system can identify potential outbreaks to improve infection control, underscoring the need for healthcare facilities to implement use of molecular-based surveillance systems to detect potential outbreaks that may be caused by multidrug-resistant organisms (MDROs). The research was conducted under the support of the CDC Prevention Epicenters Program and affiliated with the REALM project, a multi-hospital voluntary surveillance network for monitoring multidrug-resistant organisms among Chicago hospital intensive care units and long-term acute care hospitals.
The Product Development and Management Association (PDMA), the premier global advocate for product development and management professionals, announced today that it has awarded the 2015 Outstanding Corporate Innovator (OCI) Award to BD (Becton, Dickinson and Company) (NYSE: BDX).
BD's focus on innovation has provided a framework to integrate the business, make acquisitions and coordinate actions vertically, from the top through operating levels of the company.
Every startup is built on a number of assumptions and undoubtedly some of them will be incorrect. At Dreamit, I’m always stressing the importance of accurately identifying those assumptions and de-risking them as early in the process as possible.
A simple example I like to use involves the e-commerce shoe company Zappos. One of the key assumptions Zappos was built on is the idea that people are willing to buy shoes online. From our 2015 perspective that sounds glaringly obvious but in 1999 that wasn’t the case. The founders tested the market early on and determined there was a demand for the service. It would’ve been a waste of energy and resources to develop the idea if that base assumption had turned out to be wrong.
Madison healthcare IT startup Redox won a prestigious award at a national healthcare technology conference this week.
Redox, which helps app developers get access to electronic health records and health systems manage their connections to the cloud, beat out nearly 100 startups to win a pitch competition at Health 2.0, a leading healthcare technology conference in San Francisco.
Immunomic Therapeutics, a biotechnology company developing a new type of vaccine based on Johns Hopkins research, has reached a $300 million deal licensing its technology to Japanese company Astellas Pharma.
Astellas will be able to use Immunomic's vaccine design to develop products that treat or prevent allergic diseases under the deal. Immunomic will receive an up-front $300 million payment and then 10 percent royalties on sales Astellas gets using the technology. It also retains the rights to use its vaccine methods on other types of diseases, including cancer.
Gaithersburg-based Novavax, Inc., (Nasdaq: NVAX) a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants, announced positive top-line data from a Phase 2 clinical trial of its RSV F-protein recombinant nanoparticle vaccine candidate (RSV F Vaccine) to protect infants via maternal immunization.
Novavax also announced it has been awarded a grant of up to $89 million by the Bill & Melinda Gates Foundation to support development of the RSV F Vaccine Phase 3 clinical trial in pregnant women, planned to initiate during the first quarter of 2016.
Blackstone Group LP agreed to buy BioMed Realty Trust Inc, a supplier of office space to healthcare companies, in a deal valued at $8 billion, adding to the private equity firm's huge real estate portfolio.
BioMed's shares were up 8.6 percent at $23.45 in premarket trading, just shy of the offer price of $23.75.